BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32629139)

  • 1. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
    Lebeaux D; Revest M
    Travel Med Infect Dis; 2020; 36():101819. PubMed ID: 32629139
    [No Abstract]   [Full Text] [Related]  

  • 2. Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
    Bonny A; Talle MA; Ngantcha M; Tayebjee MH
    Travel Med Infect Dis; 2020; 37():101861. PubMed ID: 32889105
    [No Abstract]   [Full Text] [Related]  

  • 3. Hydroxychloroquine and azithromycin as a treatment of COVID-19.
    Fanin A; Calegari J; Beverina A; Tiraboschi S;
    Intern Emerg Med; 2020 Aug; 15(5):841-843. PubMed ID: 32474851
    [No Abstract]   [Full Text] [Related]  

  • 4. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?
    Popescu CP; Fischer PR
    Travel Med Infect Dis; 2020; 35():101764. PubMed ID: 32485391
    [No Abstract]   [Full Text] [Related]  

  • 5. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.
    Lagier JC; Million M; Gautret P; Colson P; Cortaredona S; Giraud-Gatineau A; Honoré S; Gaubert JY; Fournier PE; Tissot-Dupont H; Chabrière E; Stein A; Deharo JC; Fenollar F; Rolain JM; Obadia Y; Jacquier A; La Scola B; Brouqui P; Drancourt M; Parola P; Raoult D;
    Travel Med Infect Dis; 2020; 36():101791. PubMed ID: 32593867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center.
    Pothen L; Yildiz H; De Greef J; Penaloza A; Beauloye C; Belkhir L; Yombi JC
    Travel Med Infect Dis; 2020; 36():101788. PubMed ID: 32540396
    [No Abstract]   [Full Text] [Related]  

  • 7. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
    Million M; Lagier JC; Gautret P; Colson P; Fournier PE; Amrane S; Hocquart M; Mailhe M; Esteves-Vieira V; Doudier B; Aubry C; Correard F; Giraud-Gatineau A; Roussel Y; Berenger C; Cassir N; Seng P; Zandotti C; Dhiver C; Ravaux I; Tomei C; Eldin C; Tissot-Dupont H; Honoré S; Stein A; Jacquier A; Deharo JC; Chabrière E; Levasseur A; Fenollar F; Rolain JM; Obadia Y; Brouqui P; Drancourt M; La Scola B; Parola P; Raoult D
    Travel Med Infect Dis; 2020; 35():101738. PubMed ID: 32387409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.
    Hor CP; Hussin N; Nalliah S; Ooi WT; Tang XY; Zachariah S; Jugindar Singh GPS; Abdul Rani R; Perumal K; Cheah WK
    J Infect; 2020 Aug; 81(2):e117-e119. PubMed ID: 32474031
    [No Abstract]   [Full Text] [Related]  

  • 9. Comment on Arshad et al.: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.
    Varisco TJ; Johnson ML; Thornton D
    Int J Infect Dis; 2020 Oct; 99():373. PubMed ID: 32771630
    [No Abstract]   [Full Text] [Related]  

  • 10. Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.
    Parra-Lara LG; Martínez-Arboleda JJ; Rosso F
    J Glob Antimicrob Resist; 2020 Sep; 22():680-684. PubMed ID: 32622008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.
    Frigerio M
    Int J Cardiol; 2020 Oct; 316():285-286. PubMed ID: 32473921
    [No Abstract]   [Full Text] [Related]  

  • 12. Possible synergistic effects of hydroxychloroquine and steroids in COVID-19, time for a nuanced approach. Comment on Arshad et al.
    Wiseman DM
    Int J Infect Dis; 2020 Oct; 99():344-345. PubMed ID: 32768694
    [No Abstract]   [Full Text] [Related]  

  • 13. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19.
    Intson K; Kumar S; Botta A; Neckles R; Leung C; Jawaid A
    Swiss Med Wkly; 2020 Apr; 150():w20262. PubMed ID: 32347963
    [No Abstract]   [Full Text] [Related]  

  • 14. Problems with the analysis in "Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19".
    Atkinson JG
    Int J Infect Dis; 2020 Oct; 99():37. PubMed ID: 32738492
    [No Abstract]   [Full Text] [Related]  

  • 15. Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.
    Rosendaal FR
    Int J Antimicrob Agents; 2020 Jul; 56(1):106063. PubMed ID: 32674928
    [No Abstract]   [Full Text] [Related]  

  • 16. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.
    Bonow RO; Hernandez AF; Turakhia M
    JAMA Cardiol; 2020 Sep; 5(9):986-987. PubMed ID: 32936259
    [No Abstract]   [Full Text] [Related]  

  • 17. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
    Gautret P; Lagier JC; Parola P; Hoang VT; Meddeb L; Mailhe M; Doudier B; Courjon J; Giordanengo V; Vieira VE; Tissot Dupont H; Honoré S; Colson P; Chabrière E; La Scola B; Rolain JM; Brouqui P; Raoult D
    Int J Antimicrob Agents; 2020 Jul; 56(1):105949. PubMed ID: 32205204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials.
    Malviya A
    Int J Infect Dis; 2020 Oct; 99():310-311. PubMed ID: 32738490
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA).
    Dar SA; Wahid M; Haque S; Almalki SS; Akhter N
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):7923-7924. PubMed ID: 32767316
    [No Abstract]   [Full Text] [Related]  

  • 20. Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19.
    Mazzitelli M; Davoli C; Scaglione V; Fusco P; La Gamba V; Matera G; Trecarichi EM; Torti C
    Travel Med Infect Dis; 2020; 37():101826. PubMed ID: 32739472
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.